作者: Shiming Zhang , Yuanhang Sun , Le Zhou , Zhujun Jiang , Xinggang Yang
DOI: 10.1016/J.IJPHARM.2020.119759
关键词:
摘要: Abstract The purpose of this study is to improve in vitro dissolution and vivo bioavailability the poorly soluble drug cilostazol (CLT) through amorphous solid dispersion technology, prepared a stable supersaturated drug-loaded system problem high free energy instability traditional dispersions. optimized formulation CLT: Syloid®244FP: Kolliphor®P188 = 1:1.5:1.5 (CLT-SD), where co-loading Syloid®244FP Kolliphor®P188 has synergistic effect. Drug polymers interactions morphology were estimated by physicochemical characterization, including DSC XRD, SEM, TEM, FT-IR, Specific area analysis. Optimized kept most an state without significant change dissolution, which could be maintained for at least 1 year. was further into osmotic pump tablets controlled-release drugs. three preparations (CLT, CLT-SD, tablets) evaluated Beagle dogs, results clarified that oral CLT-SD improved as compared with CLT powder achieved In conclusion, drugs mesoporous silica hydrophilic polymer compounds can guiding future modification method delivering loading systems.